SCHEMBL6776908

SCHEMBL6776908

O=C(O)CCNC(=O)CNC(=O)c1cccc(NC(=O)NCc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
PPARG P37231 2/20 0.50
LMNA P02545 2/20 0.50
EGLN2 Q96KS0 1/20 0.50
EGLN1 Q9GZT9 1/20 0.50
KDR P35968 1/20 0.50
SENP1 Q9P0U3 2/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
MITF O75030 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 2/20 0.48
HTT P42858 2/20 0.48
HPGD P15428 1/20 0.48
EPHX2 P34913 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorobenzene SCHEMBL7832714 0.95 KDM4E (0.52) MAPK1PPARGLMNAEGLN2EGLN1
SCHEMBL7823595 0.94 KDM4E (0.53) LMNAKDRRAB9ANPC1KMT2A
SCHEMBL27484436 0.90 KMT2A (0.56) LMNASENP1RAB9ANPC1KMT2A
SCHEMBL7837395 0.87 NAMPT (0.53) MAPK1LMNAKDRRAB9ANPC1
SCHEMBL6773426 0.83 MAPK1 (0.45) MAPK1PPARGLMNAKDRSENP1
SCHEMBL7347796 0.83 EPHX2 (0.52) LMNAKMT2AALDH1A1HTTEPHX2
SCHEMBL8500095 0.82 PPARG (0.59) MAPK1PPARGLMNAKDRSENP1
SCHEMBL7856448 0.82 PPARG (0.68) MAPK1PPARGLMNAKDRSENP1
SCHEMBL6773153 0.81 ITGB3 (0.55) KMT2AHTTEPHX2L3MBTL1SMN1; SMN2
SCHEMBL7833496 0.81 ITGB3 (0.58) MAPK1LMNAKDRSENP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
CN-1201454-A Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists SEARLE & CO (US) 1998-12-09 CN claimed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP claimed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed